Fig. 5

Baicalin and wogonoside enhanced cell viability in the high glucose condition in human podocyte cells. a Human podocyte cells were preconditioned with a series concentration of baicalin for 48 h and measured by Cell Count-8 assay. *Compared with 0 mg/L group, n = 3. b Human podocyte cells were preconditioned with a series concentration of wogonoside for 48 h and measured by Cell Count-8 assay. *Compared with 0 mg/L group, n = 3. c Human podocyte cells were treated with baicalin (5 or10 mg/L) or wogonoside (5 or10 mg/L) for 1 h and co-incubated with MO or HG for 48 h, then measured by Cell Count-8 assay. *Compared with control group. # Compared with HG group, n = 3. d, e Human podocyte cells were preconditioned with or without baicalin (5 or10 mg/L) or wogonoside (5 or 10 mg/L) for 1 h and treated with or without HG (30 mmol/L) for 24 h. The expression of podocin was tested by western blotting. Control: normal glucose condition (5 mM D-glucose); DMSO:dimethyl sulfoxide; HG: high glucose condition (30 mM D-glucose); MA (mannitol, 5 mM D-glucose + 25 mM mannitol)